Identification, Characterization and Targeting of Cancer Stem Cells DVD
About the DVD:
This short course reports on the considerable progress of identifying and validating specific targets on stem cells that are not present on other cells, and on specific therapeutics for these targets and for stem cell specific pathways that inhibit tumour growth and reduce CSC frequency. Moreover it covers new studies that focus on gene expression signatures revealing new therapeutic targets that are providing promising results in prostate cancers.
About the Conference:
The one scientific event for cutting-edge research, trends and analysis. The future holds great promise for molecular medicine, however the demand for results today is ever mounting, from both patients and businesses alike. The Molecular Med Tri-Con is the place to find the tools to turn ‘someday’ into ‘now’. ATTEND. DISCOVER. APPLY.
This DVD includes two bonus presentations including: “Deconstructing the Drug Development Process: The New Face of Innovation” and “To the $1,000 Genome — and Beyond”
Molecular Med TRI-CON 2011 – a LIFE changing event
About the DVD:
Over 129 Slides
Individual Copy: $345
Site License: $1380
Agenda At A Glance:
Targeting Cancer Stem Cells with Antibodies: New Opportunities, Approaches, and Challenges for Cancer Drug Development
Robert Hollingsworth, Ph.D., Director, Cancer Biology, MedImmune, Inc.
At MedImmune we're harnessing our state-of-the-art target discovery and antibody drug development capabilities to create novel medicines that inhibit cancer stem cells. My talk will describe MedImmune's therapeutic antibody platforms, and give examples of how we're employing these to develop several anti-cancer drugs, including cancer stem cell inhibitors. I'll also describe innovative approaches to the identification and evaluation of new cancer stem cell targets and cellular self-renewal targets. Finally, my talk will highlight several challenges that must be addressed in the development of cancer stem cell drugs and provide views on how these might be surmounted.
Biography: Dr. Robert Hollingsworth is Director of Cancer Biology at MedImmune, the biologics subsidiary of AstraZeneca. He oversees preclinical research ranging from target identification to in vivo lead testing, including development of new antibody-drug conjugates for cancer therapy. One of his MedImmune teams is focused on dissecting the function of cancer stem cells and finding novel CSC inhibiting biotherapeutics. Prior to joining MedImmune, Dr. Hollingsworth served as a Director at GlaxoSmithKline for eleven years, working in the oncology, virology, and genomics research. He has been involved in numerous important cancer research discoveries, including early insights into the role of the microenvironment in tumorigenesis, the function of tumor suppressor proteins, cell cycle control, and the identification of biomarkers for cancer. He has also contributed to the development of several cancer drugs, including Tykerb (lapatinib).
Development of New Therapeutic Agents that Reduce Tumor Initiating Cell Frequency
Timothy Hoey, Ph.D., Senior Vice President, Oncology, OncoMed Pharmaceuticals, Inc.
Cancer stem cells (or tumor initiating cells) mediate tumor progression, metastasis, and recurrence after therapy. We have developed new agents that block key CSC pathways including Notch and Wnt. Our most advanced therapeutic, which is currently in clinical testing, is an antibody that blocks the Notch ligand DLL4. Anti-DLL4 treatment inhibits tumor growth through multiple mechanisms and reduces CSC frequency.
Biography: Dr. Timothy Hoey is Sr. Vice President, Cancer Biology at OncoMed Pharmaceuticals. His group is responsible for developing new drugs targeting cancer stem cells and biomarkers indicative of CSC frequency. Dr. Hoey previously served as Director, Biology Department at Amgen (San Francisco) and was responsible for characterization of oncogenes and development of drugs to target these oncogene products. Prior to this he was Director, Biology Department , Tularik, responsible for Cancer and Immunology research. Prior to joining Tularik, he performed post doctoral studies on transcriptional regulation at UC Berkeley under Dr. Robert Tijian. Dr. Hoey received a Ph.D. from Columbia University, where he conducted research on regulation of gene expression with Dr. Michael Levine, and a B.S. from the University of Michigan. Dr. Hoey is co-inventor on several patents and author or co-author of over 50 scientific publications.
Drug Targets for New Classes of Cancer Drugs that Fundamentally Change the Management of Prostate Cancer
Norman J. Maitland, Ph.D., Chief Scientific Officer, Procure Therapeutics Ltd.
The initial prostate CSC targets were selected from genes over-expressed in a cancer-specific rather than a differentiation specific fashion in prostate CSC’s. These genes were then subjected to specific siRNA mediated knock-down to explore their impact on CSC fate. I will explore the challenges in developing new therapeutics based on this regime and the wider implications of introducing a cancer stem cell based therapy into the clinic particularly, the means of pre-clinical testing and clinical monitoring of such therapies.
Biography: Norman J Maitland has held, since 1991, the YCR Chair of Molecular Biology at the University of York, UK, where he is also Director of the YCR Cancer Research Unit, and holds a chair in the Hull-York Medical School. He founded Pro-Cure Therapeutics in 2001 and is currently Chief Scientific Officer for the company. He gained a First Class Honours degree in Biochemistry at the University of Glasgow and a PhD in Cancer Studies from the University of Birmingham. After research training as a Robertson Research Fellow at Cold Spring Harbor Laboratory (USA) and the University of Edinburgh (UK) Dr Maitland was appointed to the first UK Lectureship in Molecular Pathology at the University of Bristol to apply molecular genetics for the analysis of primary clinical material from oral and paediatric embryonal tumours. In 2009, Dr Maitland was awarded the EAU Chopin Prize for excellence in translational research in prostate cancer.
Research in the YCR Unit, funded by Yorkshire Cancer Research, EU Framework Programmes, the US Dept of Defense and other Charitable and government sources is currently focused on the development of new therapies for human prostate cancer, based on a better understanding of the basic biology of the tumour. The research includes a particular emphasis on the biology of and gene expression patterns in prostate stem cells, multicellular models of prostate cancers and gene transfer vectors to direct gene expression specifically to tumour cells. Development of therapeutics is carried out in Pro-Cure Therapeutics, now an independent Biotech company based in York.
Enhanced Identification and Effective Targeting of Cancer Stem Cells in Human Glioblastoma Tumors using a Combination of EGFRvIII and CD133
Albert J. Wong, Professor, Cancer Biology and Neurosurgery, Stanford University Medical Center
Anti-EGFRvIII and anti-CD133 antibodies were used to identify a cancer stem cell population in primary glioblastoma that have greater self-renewal and tumorigenicity than cells identified using anti-CD133 alone. A recombinant antibody simultaneously targeting EGFRvIII/CD133 was developed that is more effective in preventing orthotopic human tumors in NOD-SCID mice than anti-EGFRvIII or anti-CD133. This recombinant antibody is now being developed for Phase I trials.
Biography: Albert Wong, M.D., received his B.A. and M.D. degrees from the Johns Hopkins University. He interned in Pediatrics at the Johns Hopkins Hospital and then did postdoctoral training at the Hopkins Oncology Center under Dr. Bert Vogelstein. He held faculty positions at the Fox Chase Cancer Center and the Thomas Jefferson University from 1989-2005, being promoted to Full Professor in 2003. Dr. Wong then joined the Dept. of Neurosurgery at Stanford University in 2005. He also founded the biotech company Alteris Therapeutics, and as its President successfully led the acquisition by Celldex Therapeutics. He has served on numerous review committees for the National Institutes of Health and the American Cancer Society, has been an advisor to several universities and pharma companies, and has been recognized with several honors, including Who’s Who in America, and finalist as Biotech Company of the Year (Philadelphia region). Dr. Wong has made several key discoveries, including the identification of the EGFRvIII alteration and the Gab1 signaling molecule. He was also the first to show that EGFRvIII could be used as the basis for a peptide vaccine as a therapeutic for brain tumors in addition to its use as a cancer stem cell marker.
Targeting Telomerase in Cancer Stem Cells
Stephen Kelsey, M.D., E.V.P. & Chief Medical Officer, Oncology, Geron Corp.
Telomerase expression is upregulated in cancer cells and particularly in the progenitor cell subcompartment of tumors. Inhibition of telomerase with a 13mer oligonucleotide (imetelstat, GRN163L) can numerically reduce the stem cell compartment of tumors and inhibit clonogenic growth in vitro and in vivo. Phase I studies have been completed and phase II studies are underway in NSCLC, breast cancer, myeloma and myeloproliferative diseases.
Biography: Stephen M. Kelsey, M.D., F.R.C.P., F.R.C.Path., has served as our as Executive Vice President and Chief Medical Officer, Oncology since April 2009. From June 2002 until April 2009, Dr. Kelsey held various positions at Genentech, Inc., most recently as Vice-President, Clinical Hematology/Oncology. From June 2000 to June 2002, Dr. Kelsey was the Director of Clinical Affairs at Pharmacia Corporation (SUGEN, Inc.) in South San Francisco and director of global clinical development (oncology) at Pharmacia Corporation in Milan, Italy. From July 1993 to June 2000, Dr. Kelsey served as a senior lecturer in Hematology/Oncology at St. Bartholomews and the Royal London School of Medicine and Dentistry and visiting fellow at Vancouver General Hospital and Terry Fox Laboratories. Dr. Kelsey earned his B.Sc. in Pharmacology, M.B., Ch.B., and Doctorate of Medicine (M.D.) degrees from the University of Birmingham in the United Kingdom.
This DVD includes two bonus presentations including: “Deconstructing the Drug Development Process: The New Face of Innovation” delivered by Kenneth Kaitin, Ph.D., Director, Tufts Center for Study of Drug Development and “To the $1,000 Genome — and Beyond” delivered by Kevin Davies, Ph.D., Author, The $1,000 Genome; Editor-in-Chief, Bio-IT World. These two talks were presented as part of the Plenary Keynote at the Molecular Med Tri-Conference.
Deconstructing the Drug Development Process: The New Face of Innovation
Kenneth Kaitin, Ph.D., Director, Tufts Center for Study of Drug Development
For over 30 years, the Center for the Study of Drug Development at Tufts University has documented the increasing challenge of bringing new pharmaceutical products to market. To succeed in today’s competitive marketplace, research-based drug and biotech companies must not only maintain their focus on R&D efficiency and output, but they must also be able to adjust to a rapidly changing and highly volatile R&D environment. In this presentation, Dr. Kaitin will use Tufts CSDD data to document the current status of pharmaceutical R&D and explore new models of innovation.
To the $1,000 Genome — and Beyond
Kevin Davies, Ph.D., Author, The $1,000 Genome; Editor-in-Chief, Bio-IT World
The field of genome analysis has undergone a revolution in recent years. Next-generation sequencing technologies have dropped the cost of sequencing a human genome from about $1 million in 2007 to less than $10,000 in 2010, with new third- and fourth-generation technologies on the horizon. But will the arrival of the $1,000 genome have any meaningful impact on drug development and the practice of medicine? Kevin Davies, author of The $1,000 Genome will share his observations on the landmarks in next-generation sequencing. He will also highlight the challenges that remain in next-gen data generation, analysis and dissemination for the research and medical communities.